

Amendment to HB 1734-FN

1 Amend the title of the bill by replacing it with the following:

2

3 AN ACT establishing a committee to study the feasibility of establishing experimental
4 treatment centers in New Hampshire and the oversight thereof.

5

6 Amend the bill by replacing all after the enacting clause with the following:

7

8 1 Committee Established. There is established a committee to study the feasibility of
9 establishing experimental treatment centers in New Hampshire and the oversight thereof.

10 2 Membership and Compensation.

11 I. The members of the committee shall be as follows:

12 (a) Two members of the senate, appointed by the president of the senate, one of whom
13 shall be a member of the minority party.

14 (b) Three members of the house of representatives, appointed by the speaker of the
15 house of representatives, one of whom shall be a member of the minority party.

16 II. Members of the committee shall receive mileage at the legislative rate when attending to
17 the duties of the committee.

18 3 Duties. The committee shall:

19 I. Determine what would be needed for sufficient oversight of experimental treatment
20 centers by the department of health and human services, the bureau of consumer protection at the
21 department of justice, and the office of professional licensure and certification.

22 II. Solicit information and testimony from the department of health and human services, the
23 bureau of consumer protection, and the office of profession licensure and certification on what they
24 would require in terms of legislation, rules, appropriation, and any potential federal waivers to
25 properly oversee these centers.

26 III. Solicit information and testimony from the current operator of an experimental
27 treatment center or a trade group representing experimental treatment centers.

28 IV. Solicit information and testimony from a governmental oversight body from another
29 state that currently allows experimental treatment centers.

30 V. Solicit information and testimony from an individual or entity with expertise in the FDA
31 drug and device approval process.

Amendment to HB 1734-FN
- Page 2 -

1 VI. Solicit information and testimony from an individual or entity with expertise in current
2 Good Manufacturing Practice (cGMP) for drug manufacturing.

3 VII. Research experimental treatment centers in other states, including all benefits and
4 consequences of those centers in those states, including patient outcomes and costs to the state's
5 health care system.

6 VIII. Research the feasibility of proper oversight of these facilities, including oversight
7 challenges in other states that have implemented these experimental treatment centers.

8 4 Chairperson; Quorum. The members of the study committee shall elect a chairperson from
9 among the members. The first meeting of the committee shall be called by the first-named senate
10 member. The first meeting of the committee shall be held within 45 days of the effective date of this
11 section. Four members of the committee shall constitute a quorum.

12 5 Report. The committee shall report its findings and any recommendations for proposed
13 legislation to the president of the senate, the speaker of the house of representatives, the senate
14 clerk, the house clerk, the governor, and the state library on or before November 1, 2026.

15 6 Effective Date. This act shall take effect upon its passage.

Amendment to HB 1734-FN
- Page 3 -

2026-1864s

AMENDED ANALYSIS

This bill establishes a committee to study the feasibility of establishing experimental treatment centers in New Hampshire and the oversight thereof.